A Study of FZ-AD004 in Patients With Advanced Solid Tumors
Recruiting now · Phase 1
Conditions studied: Advanced and Metastatic Solid Tumor
In brief
This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.
Key facts
- Study ID
- NCT05914545
- Run by
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- People needed
- 121
- Starts
- 2023-06-12
- Expected to finish
- 2027-12-01
- Last updated by the study team
- 2026-01-22
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients able to give written informed consent;
- Age ≥ 18 and ≤ 75 years old, male or female;
- Patients have histological or cytological diagnosis with advanced solid tumors.
- Have measurable lesions defined in RECIST v. 1.1;
- Expected survival ≥ 12 weeks;
- Eastern Cancer Cooperative Group (ECOG) performance status 0-1;
- Patients of child bearing potential must agree to take contraception during the study and for 6 months after the last day of treatment.
You may not qualify if…
- Have had other malignant tumors in the past 5 years;
- Have CNS (central nervous system) metastasis with clinical symptoms;
- Had undergone major surgery or severe trauma within 4 weeks prior to the first dose;
- Had undergone systemic high-dose steroids within 2 weeks of initiation of study treatment;
- Have history of psychotropic drug abuse, alcohol or drug abuse；
- Women who are pregnant or lactating；
- Other circumstances that is deemed not appropriate for the study.
Where it is running
- Shanghai Chest Hospital — Shanghai, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.